
News|Articles|November 1, 2005
Pipeline Preview
Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Non-approvable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement























